Type size:

More than one million new cases of solid tumor cancer are diagnosed each year in the US, with four cancer types (breast, prostate, lung and colorectal) accounting for over 700,000 of these. Despite varied therapeutic modalities — surgery, radiation, chemotherapy, and biotherapeutics — healthcare providers have a critical unmet need for more accurate prognostic and diagnostic tools and more effective, safer therapeutics.

Monogram Biosciences' unique VeraTag™ technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.

A more comprehensive understanding of the biology involved in cancer cell growth and drug response, especially at the level of proteins, protein complexes and signaling pathways (which constitute the target for most drugs), is required to enable healthcare providers to select the right therapy. Effective predictive tests can identify the presence of the proteins and protein complexes upon which the drugs in question act, providing valuable information on the likelihood of a response in a particular patient. Our VeraTag technology has the capability to measure these proteins and signaling pathways in their activated state.

VeraTag™ was formerly known as eTag® during development stages.